254 related articles for article (PubMed ID: 31914953)
1. Comparing healthcare cost associated with the use of enzyme-inducing and non-enzyme active antiepileptic drugs in elderly patients with epilepsy in the UK: a long-term retrospective, matched cohort study.
Borghs S; Byram L; Chan J; Dedeken P; Logan J; Kiri V; Noack-Rink M; Patsalos PN; Thieffry S
BMC Neurol; 2020 Jan; 20(1):7. PubMed ID: 31914953
[TBL] [Abstract][Full Text] [Related]
2. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study.
Borghs S; Thieffry S; Noack-Rink M; Dedeken P; Hong LS; Byram L; Logan J; Chan J; Kiri V
BMC Neurol; 2017 Mar; 17(1):59. PubMed ID: 28335764
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit analysis, cost-effectiveness analysis, and impact of antiepileptic drugs on the risk of fracture in patients with epilepsy: A nationwide cohort study.
Cheng HH; Kung PT; Wang BR; Chiu LT; Tsai WC
Epilepsy Behav; 2020 Feb; 103(Pt A):106851. PubMed ID: 31889639
[TBL] [Abstract][Full Text] [Related]
4. Use of antiepileptic drugs and lipid-lowering agents in the United States.
Mintzer S; Maio V; Foley K
Epilepsy Behav; 2014 May; 34():105-8. PubMed ID: 24735835
[TBL] [Abstract][Full Text] [Related]
5. Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD).
Shepherd C; Koepp M; Myland M; Patel K; Miglio C; Siva V; Gray E; Neary M
BMJ Open; 2017 Oct; 7(10):e015236. PubMed ID: 28982809
[TBL] [Abstract][Full Text] [Related]
6. Healthcare utilization and costs in children with stable and uncontrolled epilepsy.
Cramer JA; Wang ZJ; Chang E; Powers A; Copher R; Cherepanov D; Broder MS
Epilepsy Behav; 2014 Mar; 32():135-41. PubMed ID: 24561658
[TBL] [Abstract][Full Text] [Related]
7. Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use.
Cramer JA; Wang ZJ; Chang E; Copher R; Cherepanov D; Broder MS
Epilepsy Behav; 2015 Mar; 44():40-6. PubMed ID: 25635369
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic burden of breakthrough seizures.
Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
[TBL] [Abstract][Full Text] [Related]
10. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.
Fishman J; Kalilani L; Song Y; Swallow E; Wild I
J Manag Care Spec Pharm; 2018 Sep; 24(9):929-938. PubMed ID: 29486142
[TBL] [Abstract][Full Text] [Related]
11. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM
Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262
[TBL] [Abstract][Full Text] [Related]
12. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: A systematic review.
Fraser LA; Burneo JG; Fraser JA
Epilepsy Res; 2015 Oct; 116():59-66. PubMed ID: 26354168
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries.
Ip Q; Malone DC; Chong J; Harris RB; Labiner DM
Epilepsy Behav; 2018 Mar; 80():208-214. PubMed ID: 29414554
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
15. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview.
Willems LM; Richter S; Watermann N; Bauer S; Klein KM; Reese JP; Schöffski O; Hamer HM; Knake S; Rosenow F; Strzelczyk A
Epilepsy Behav; 2018 Jun; 83():28-35. PubMed ID: 29649671
[TBL] [Abstract][Full Text] [Related]
16. Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study.
Kalilani L; Lu C; Pierre-Louis B; Gold M
Epilepsy Behav; 2017 Jul; 72():51-57. PubMed ID: 28575767
[TBL] [Abstract][Full Text] [Related]
17. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
18. Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records.
Powell G; Logan J; Kiri V; Borghs S
BMJ Open; 2019 Dec; 9(12):e032551. PubMed ID: 31848168
[TBL] [Abstract][Full Text] [Related]
19. Current state of the union of epilepsy care in the United States: Antiepileptic drugs - An introduction to the Connectors Project.
Sirven JI; Shafer PO; Kalilani L; Wild I; Fishman J; Owens S
Epilepsy Behav; 2018 Mar; 80():98-103. PubMed ID: 29414565
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and costs in adults with stable and uncontrolled epilepsy.
Cramer JA; Wang ZJ; Chang E; Powers A; Copher R; Cherepanov D; Broder MS
Epilepsy Behav; 2014 Feb; 31():356-62. PubMed ID: 24239435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
